GlassScriptPhysician profile
Saray Lopez
NPI 1841044609
$7,020.40
in general payments reported to CMS, 2019-2025
22 companies · $3,599 in 2025
The $3,599 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $3,422 · 2025: $3,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,909 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,908.91 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,619.10 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $935.77 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $728.09 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $525.26 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $483.01 | 2024-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $473.51 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $439.78 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $439.17 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $297.41 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $278.53 | 2024-2025 | Auvelity |
| Tris Pharma INC | $233.53 | 2024-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Idorsia Pharmaceuticals US INC | $144.48 | 2024 | Quviviq |
| Lundbeck LLC | $98.08 | 2024-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $69.29 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $66.23 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $48.63 | 2025 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $42.61 | 2024 | Trintellix |
| Lilly USA, LLC | $23.17 | 2024 | Amyvid |
| Bausch Health US, LLC | $22.42 | 2025 | Wellbutrin, Aplenzin |
| Supernus Pharmaceuticals, INC. | $19.94 | 2025 | Qelbree |
| Noven Therapeutics, LLC | $19.09 | 2024 | Xelstrym |
| Vertical Pharmaceuticals, LLC | $13.30 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saray Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.